期刊
EBIOMEDICINE
卷 64, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ebiom.2020.103160
关键词
Malignant mesothelioma; Lymphocytes; Myeloid-derived suppressor cells; Gemcitabine; Immunotherapy
资金
- Koningin Wilhelmina Fonds voor de Nederlandse Kankerbestrijding (KWF)
- Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose (NVALT) Study Group
The study showed that gemcitabine treatment in mesothelioma patients led to an increase in NK cell proliferation and a decrease in T regulatory cell proliferation, along with lower frequencies of MDSCs. Additionally, co-stimulatory molecules such as ICOS, CD28, and HLA-DR were uniformly increased across different types of T cells. Preliminary data also suggested that increased NK cell proliferation and PD-1 expression in T cells following gemcitabine treatment were associated with improved PFS and OS.
Background: Gemcitabine is a frequently used chemotherapeutic agent but its effects on the immune system are incompletely understood. Recently, the randomized NVALT19-trial revealed that maintenance gemcitabine after first-line chemotherapy significantly prolonged progression-free survival (PFS) compared to best supportive care (BSC) in malignant mesothelioma. Whether these effects are paralleled by changes in circulating immune cell subsets is currently unknown. These analyses could offer improved mechanistic insights into the effects of gemcitabine on the host and guide development of effective combination therapies in mesothelioma. Methods: We stained peripheral blood mononuclear cells (PBMCs) and myeloid-derived suppressor cells (MDSCs) at baseline and 3 weeks following start of gemcitabine or BSC treatment in a subgroup of mesothelioma patients included in the NVALT19-trial. In total, 24 paired samples including both MDSCs and PBMCs were included. We performed multicolour flow-cytometry to assess co-inhibitory and-stimulatory receptor- and cytokine expression and matched these parameters with PFS and OS. Findings: Gemcitabine treatment was significantly associated with an increased NK-cell- and decreased T-regulatory cell proliferation whereas the opposite occurred in control patients. Furthermore, myeloid derived suppressor cells (MDSCs) frequencies were lower in gemcitabine-treated patients and this correlated with increased T-cell proliferation following treatment. Whereas gemcitabine variably altered co-inhibitory receptor expression, co-stimulatory molecules including ICOS, CD28 and HLA-DR were uniformly increased across CD4(+) T-helper, CD8(+) Tand NK-cells. Although preliminary in nature, the increase in NK-cell proliferation and PD-1 expression in T cells following gemcitabine treatment was associated with improved PFS and OS. Interpretation: Gemcitabine treatment was associated with widespread effects on circulating immune cells of mesothelioma patients with responding patients displaying increased NK-cell and PD-1 + T-cell proliferation. These exploratory data provide a platform for future on treatment-biomarker development and novel combination treatment strategies. (C) 2020 The Authors. Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据